Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study has found.

1 Aug 2013

Science Exchange partners with antibodies-online to independently validate antibodies to improve research quality

Science Exchange, in partnership with the world's largest marketplace for antibodies, antibodies-online, announced today the launch of a program to independently validate thousands of commercial antibodies via the Science Exchange independent validation service.

31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis.

31 Jul 2013

Different types of happiness have surprisingly different effects on human genome

A good state of mind - that is, your happiness - affects your genes, scientists say. In the first study of its kind, researchers from UCLA's Cousins Center for Psychoneuroimmunology and the University of North Carolina examined how positive psychology impacts human gene expression.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

Saudi and UK scientists provide detailed picture of MERS coronavirus

Saudi and UK scientists provide the most detailed picture yet of the clinical and laboratory characteristics of Middle East Respiratory Syndrome (MERS) coronavirus, revealing a wide range of clinical symptoms and an extremely high death rate among patients with co-existing medical conditions.

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

New species of adenovirus can spread from monkey to human, say researchers

Adenoviruses commonly infect humans, causing colds, flu-like symptoms and sometimes even death, but now UC San Francisco researchers have discovered that a new species of adenovirus can spread from primate to primate, and potentially from monkey to human.

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one day lead to effective therapies against the virus, was published online ahead of print in the Journal of Virology.

25 Jul 2013

Scientists develop simple, inexpensive and reliable method of detecting plague pathogen

Diagnosing the presence of Yersinia pestis, the cause of plague, may soon be easier than ever before. Scientists working with Peter Seeberger, Director at the Max Planck Institute of Colloids and Interfaces (MPIKG) in Potsdam and Professor at the Freie Universit-t Berlin, have come up with a simple, inexpensive and reliable method of detecting the bacterium.

25 Jul 2013

Faulty genetic pathway is a potent player in many types of allergies, say researchers

Newly published research by investigators at the Johns Hopkins Children's Center and the Johns Hopkins Institute of Genetic Medicine reveals that a faulty genetic pathway already known for its role in some connective tissue disorders is also a potent player in many types of allergies.

25 Jul 2013

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.

24 Jul 2013

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when it's exposed to the real thing.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.

18 Jul 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

Antibody News and Research

Further Reading

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Science Exchange partners with antibodies-online to independently validate antibodies to improve research quality

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Different types of happiness have surprisingly different effects on human genome

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

Saudi and UK scientists provide detailed picture of MERS coronavirus

Technique for developing more targeted drugs using molecular "robots"

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

New species of adenovirus can spread from monkey to human, say researchers

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Scientists develop simple, inexpensive and reliable method of detecting plague pathogen

Faulty genetic pathway is a potent player in many types of allergies, say researchers

Genentech announces that Phase III CLL11 study meets primary endpoint

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Kolltan signs research agreement with CHOP for novel therapeutic approaches for neuroblastoma

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo